Chloride-dependent mechanisms contribute to urinary bladder smooth muscle contractility: Pharmacological and molecular evidence from rat bladder tissue Authors: Yuh-Chen Kuo, Vincent F. S. Tsai, Shih-Ping Liu, Jyh-Horng Chen, Hong-Chiang Chang, Ju-Ton Hsieh Published: 2026 ABSTRACT ABSTRACTObjectives:To investigate the functional role of chloride-dependent signaling pathways in urinary bladder smooth muscle (SM) contractility and to evaluate the expression of ClC-3 and CLCA4 in rat bladder tissue.Materials and Methods:Expression of ClC-3 and CLCA4 in rat bladder tissue was examined using Western blotting and immunohistochemistry. Functional studies were conducted using isolated bladder SM strips (2 mm × 2 mm × 10 mm) from adult male Wistar rats mounted in organ bath chambers for isometric tension recording. Potassium chloride (KCl)-induced contractions were assessed under varying extracellular chloride concentrations (138–8 mM) and after substitution with Br− or I− . Norepinephrine (NE)-induced contractions were evaluated with pretreatment of chloride transport inhibitors (bumetanide, HEPES without bicarbonate, and ethacrynic acid) and chloride channel blockers (4,4’-diisothiocyano-2,2’-stilbene-disulfonic acid, anthracene-9-carboxylic acid, and niflumic acid) at different concentrations.Results:ClC-3 and CLCA4 were expressed in both urothelial and SM layers. Reduction of extracellular chloride concentration significantly attenuated KCl-induced contractions in a concentration-dependent manner (P < 0.01) and substitution with bromide or iodide produced similar effects. Chloride transport inhibitors and channel blockers significantly and dose-dependently suppressed NE-induced contractions (all P < 0.01). The inhibitory effects were consistently observed across multiple pharmacological interventions.Conclusion:The present study provides pharmacological and molecular evidence supporting a contributory role of chloride-dependent signaling in bladder SM contractility under ex vivo conditions. Expression of ClC-3 and CLCA4 in urothelial and SM layers further suggests that chloride-dependent regulation may involve multiple bladder compartments. Although the precise molecular mechanisms remain incompletely defined, these findings support further investigation into chloride-dependent signaling pathways in bladder physiology and dysfunction. INTRODUCTION Bladder smooth muscle (SM) contractility is regulated through coordinated interactions between intracellular calcium signaling, membrane excitability, and ion transport mechanisms. Alterations in these pathways contribute to abnormal bladder function, including detrusor overactivity and impaired bladder compliance. Although calcium and potassium channels are well-established modulators of bladder SM excitability, the physiological contribution of chloride (Cl−)-dependent signaling pathways remains incompletely understood. In many SM tissues, chloride channels and chloride transport mechanisms contribute to membrane depolarization and contractile regulation by influencing electrochemical gradients and calcium entry [12345]. Among these pathways, the CLC family member ClC-3 has been implicated in cell volume regulation, membrane excitability, and SM function [67]. In addition, calcium-activated chloride channels (CaCCs), particularly Anoctamin-1 (Ano1/TMEM16A), have been shown to modulate SM excitability [89]. Activation of these channels has been proposed to facilitate membrane depolarization and enhance calcium-dependent contraction in several SM systems. Although chloride channels have been studied in various cell types including cardiac myocytes, epithelial cells, endothelial cells, neurons, vascular SM, and penile SM cells [891011121314], literature regarding their role in urinary bladder SM remains limited. Previous bladder studies have reported increased CaCC activity in detrusor overactivity associated with partial bladder outlet obstruction [15], and Ano1/TMEM16A has been implicated in spontaneous phasic contraction of rat bladder strips [16]. However, most previous investigations have focused mainly on spontaneous or phasic activity, whereas the contribution of chloride-dependent pathways to sustained agonist-induced bladder contraction remains incompletely characterized. Furthermore, the distribution and potential functional involvement of ClC-3-associated pathways and chloride channel-related regulatory proteins such as CLCA4 in bladder tissue have not been fully investigated. Based on the established role of chloride-dependent conductance in SM excitability, we hypothesized that chloride-dependent signaling pathways contribute functionally to urinary bladder SM contractility. Therefore, the present study aimed to investigate the distribution of ClC-3 and CLCA4 in rat bladder tissue and evaluate the effects of extracellular chloride manipulation and pharmacological interference with chloride-related pathways on bladder SM contraction. MATERIALS AND METHODS Tissue preparation Male Wistar rats weighing 250–300 g were used in this study. Animals were anesthetized with intraperitoneal pentobarbital and euthanized by CO2 inhalation followed by cervical dislocation. Urinary bladders were rapidly excised, and the mucosa and surrounding connective tissues were carefully removed under microscopic dissection [17]. SM specimens from the bladder body were prepared either for protein extraction or cut into strips measuring approximately 2 mm × 2 mm × 10 mm for organ bath experiments. Whole bladder tissues were preserved for immunohistochemistry. Protein extraction and western blot analysis Bladder SM tissues were homogenized at 4°C in Tris-HCl buffer containing ethylenediaminetetraacetic acid (EDTA), protease inhibitors, IGEPAL CA-630, and sodium deoxycholate. Homogenates were centrifuged to remove cellular debris, and protein concentrations were determined using the bicinchoninic acid assay. Protein samples (30 µg/lane) were separated on 8% SDS–polyacrylamide gels and transferred onto nylon membranes (Bio-Rad). Membranes were blocked with BOTTO solution and incubated overnight with ClC-3 polyclonal antisera (Alomone Labs, Jerusalem, Israel) or anti-CLCA4 polyclonal antibody (Sigma-Aldrich, St. Louis, MO, USA), both at 1:200 dilution. After washing, membranes were incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG secondary antibody (1:2000; Chemicon International, Temecula, CA, USA). Immunoreactive bands were visualized using enhanced chemiluminescence reagents and Hyperfilm (Amersham, England). Immunohistochemistry Bladder tissues were fixed in 4% paraformaldehyde prepared in PBS and subsequently cryoprotected in graded sucrose solutions (5%–20%). Tissues were embedded in Tissue-Tek mounting medium (Miles, IL, USA), frozen in liquid nitrogen–cooled isopentane, and sectioned at 10 µm thickness using a Leica CM3500 cryostat. Frozen sections were mounted on Vectabond-treated glass slides (Vector Laboratories, Burlingame, CA, USA). After blocking nonspecific binding with 10% bovine serum albumin for 1 h, sections were incubated overnight with primary antibodies against ClC-3 or CLCA4. Following PBS washes, sections were treated with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:2000 dilution; Sigma-Aldrich). Immunoreactivity was visualized using 3,3’-diaminobenzidine substrate solution, and sections were counterstained with hematoxylin. Negative controls were prepared either by omission of primary antibodies or by preabsorption with corresponding antigen peptides before incubation. Images were digitally processed using Adobe Photoshop software (Mountain View, CA, USA). Organ bath preparation Bladder SM strips were mounted in 25 mL organ bath chambers (Radnoti Glass, ADInstruments, Dunedin, New Zealand) and attached to isometric force transducers using stainless steel wires. Mechanical activity was monitored through a transducer amplifier system connected to a PowerLab/800 data acquisition unit (ADInstruments). Contractile responses were continuously recorded and analyzed using PowerLab software version 4.0 (ADInstruments). Tissue strips were equilibrated under a resting tension of 5 g for 120 min at 37°C in aerated physiological salt solution (PSS) continuously bubbled with 95% O2 and 5% CO2. The PSS contained the following components (mM): NaCl 130, Potassium chloride (KCl) 4.7, KH2PO4 1.18, MgSO4·7H2O 1.17, NaHCO3 14.9, CaCl2·H2O 1.6, glucose 5.5, and CaNa2-EDTA 0.03 (pH 7.30). Preparation of low-chloride buffer and anion substitution Low-chloride buffer was prepared by replacing NaCl with 130 mM NaOH followed by pH adjustment to 7.30 using methanesulfonic acid. Osmolarity was measured using a vapor pressure osmometer (Wescor 5500, Artisan, IL, USA) and was comparable between low-chloride and control solutions. Different extracellular chloride concentrations were generated by mixing standard PSS with low-chloride buffer at predefined ratios. For anion substitution experiments, NaCl was completely replaced with equimolar NaBr or NaI. HEPES-buffered solutions were prepared by replacing bicarbonate with 10 mM HEPES and adjusting pH to 7.30 using NaOH. In experiments involving rapid extracellular chloride exchange, low-chloride solutions were prewarmed and preaerated before rapid replacement of bath solution in the organ chamber. Control experiments were performed using identical solution exchange procedures. Dose–response and inhibitory dose–response contractions Bladder SM contractions were induced using KCl or norepinephrine (NE). After washout and re-equilibration, cumulative concentration–response curves were generated by sequential addition of increasing agonist concentrations. The effective dose producing approximately 80% maximal contraction (ED80) was determined for each agonist. To investigate chloride-dependent mechanisms, KCl-induced contractions were evaluated under varying extracellular chloride concentrations ranging from 138 mM to 8 mM and during substitution of extracellular chloride with bromide or iodide. In separate experiments, NE-induced contractions were examined after pretreatment with chloride transport inhibitors, including bumetanide (BUM), bicarbonate-free HEPES-buffered solution, and ethacrynic acid (ETH), as well as chloride-channel blockers including 4,4’-diisothiocyano-2,2’-stilbene-disulfonic acid (DIDS), anthracene-9-carboxylic acid (A9C), and niflumic acid (NFA). These pharmacological agents were selected because they are widely used experimental tools for investigating chloride-dependent signaling pathways in SM physiology [18192021]. BUM and ETH were used to interfere with chloride transport mechanisms, particularly Na+-K+-2Cl− cotransport pathways. DIDS, A9C, and NFA were employed as chloride-channel/CaCC inhibitors. Bicarbonate-free HEPES-buffered solution was additionally used to reduce bicarbonate-dependent chloride transport activity. All inhibitors were tested over concentrations ranging from 10−8 to 1 M to generate inhibitory dose–response curves and determine the half-maximal inhibitory concentration (IC₅₀) for each antagonist. Reagents and data analysis Contractile responses were continuously monitored for 20 min. KCl-induced contractions were produced using a 1 M KCl stock solution. Under low-chloride conditions, potassium methanesulfonate solution was used to maintain extracellular potassium concentration without increasing chloride content. Calcium-free PSS was prepared by omission of CaCl2 without use of calcium-chelating agents. Bladder SM contraction exhibited biphasic responses consisting of an initial transient phase and a sustained tonic phase [Supplementary Figure 1]. At lower agonist concentrations, transient peak tension was typically observed at approximately 3 min and exceeded subsequent stabilized tension; therefore, contractile responses were quantified as peak tension at 3 min and steady-state tension at 20 min. At higher agonist concentrations, tension increased rapidly within the first 5 min and plateaued by approximately 20 min. These responses were quantified at 5 and 20 min. NE and DIDS were dissolved in aqueous solution. BUM was dissolved in ethanol, whereas ETH, NFA, and A9C were dissolved in dimethyl sulfoxide. Final solvent concentrations did not exceed 0.1%. Each bladder strip was used for only one pharmacological protocol to minimize residual drug effects or experimental carryover. Data are presented as mean ± standard error of the mean, with n representing the number of animals. Statistical analysis was performed using Student’s t-test, and P < 0.05 was considered statistically significant. English language editing assistance was provided using ChatGPT (OpenAI, San Francisco, CA, USA). Ethics approval All animal procedures were approved by the Institutional Animal Care and Use Committee of the National Taiwan University College of Medicine (Approval No.: 20120035). RESULTS Expression of chloride channels Western blot and immunohistochemistry demonstrated expression of ClC-3 and CLCA4 in both urothelial and SM layers of rat bladder tissue [Figure 1]. Western blot analysis and immunohistochemistry of ClC-3 or CLCA4 protein on rat bladder tissue. (a) By Western blot method, the expression of both ClC-3 and CLCA4 proteins on rat bladder tissue could be determined. (b and c) The immunohistochemistry revealed expressions of ClC-3 or CLCA4 proteins located on both urothelium and bladder smooth muscle tissue of rat with an original magnification of ×400 Contractile responses of bladder smooth muscle to potassium chloride and norepinephrine KCl and NE elicited concentration-dependent contractions in bladder SM. KCl-induced contraction increased progressively with rising extracellular K+ concentrations, reaching a maximal response at high concentrations. Similarly, NE produced a concentration-dependent increase in contractile force, with a sustained plateau at higher concentrations [Figure 2]. The calculated ED₈₀ values were used for subsequent functional experiments. Agonists-induced contractions. (a) Representative traces showing bladder smooth muscle contractions in response to increasing agonist concentrations. (b) Dose response curve of agonists (n = 6 in each experiment). The contractility increased as the concentration of agonists increased. **P < 0.01 when compared with the tension at the lowest concentration of agonists. Kcl: Potassium chloride, NE: Norepinephrine Effects of extracellular Cl − concentration on potassium chloride-induced contraction Reduction of extracellular chloride concentration ([Cl−]e) markedly attenuated KCl-induced contractions. Lowering [Cl−]ₑ from 138 mM to 8 mM resulted in a significant decrease in contractile force (P < 0.01) [Figure 3a]. The effects of altered extracellular Cl− concentration or anion substitution to agonist-induced contractions. (a) Alteration of extracellular Cl− concentration. (n = 6). The maximal contractility decreased significantly as the concentration of extracellular chloride changed from 138 to 8 mM. (**P < 0.01). (b) Substitution of Cl− by Br−, I− (n = 6). The contractility decreased significantly as the extracellular Cl. was substituted by Br. or I. (**P < 0.01) Substitution of Cl− with Br− or I− resulted in a significant reduction in contractile response (P < 0.01) [Figure 3b]. These findings indicate that extracellular Cl− plays a critical role in KCl-induced bladder SM contraction. Effects of chloride transport inhibitors on norepinephrine-induced contraction Pretreatment with chloride transport inhibitors significantly attenuated NE-induced contractions. BUM, HEPES-buffered solution without bicarbonate, and ETH all reduced contractile responses compared with control conditions [Figure 4a]. Pharmacological inhibition of chloride transport inhibitors and channel blockers on Norepinephrine (NE)-induced contraction. (a) Inhibitory dose response curve of chloride transport inhibitors (n = 6 in each experiment). Pretreatment with BUM, HEPES without bicarbonate or ETH significantly decreased the contractility induced by NE (ED80). *P < 0.05 when compared with the tension at ED80 of NE without pretreatment. **P < 0.01 when compared with the tension at ED80 of NE without pretreatment. (b) Inhibitory dose response curve of chloride channel blockers (n = 6 in each experiment). Pretreatment with 4,4’- diisothiocyano-2,2’- stilbene-disulfonic acid, A9C or niflumic acid significantly decreased the contractility induced by NE (ED80). *P < 0.05 when compared with the tension at ED80 of NE without pretreatment. **P < 0.01 when compared with the tension at ED80 of NE without pretreatment These findings suggest that chloride transport mechanisms contribute to NE-induced bladder SM contraction. Effects of chloride channel blockers on norepinephrine-induced contraction Chloride channel blockers also significantly reduced NE-induced contractions. Treatment with DIDS, A9C, and NFA resulted in marked attenuation of contractile force [Figure 4b]. The magnitude of inhibition was comparable among the different blockers, indicating a functional role for chloride channels in mediating contractile responses. Inhibitory effects of chloride transport inhibitors and channel blockers at IC50 on agonist-induced contractions at ED80 NE (ED80) elicited a sustained contraction of bladder SM. Pretreatment with chloride transport inhibitors and channel blockers at their respective IC50 concentrations significantly reduced contractile responses. BUM decreased contraction by ~40%–50%, while HEPES-buffered solution (bicarbonate-free) reduced responses by ~30%–40%. ETH produced a comparable inhibition (~35%–45%). Among chloride channel blockers, DIDS, A9C, and NFA attenuated contraction by ~30%–50%. All reductions were statistically significant [P < 0.05; n = 6 respectively; Figure 5]. Comparison of inhibitory responses of chloride transport inhibitors (n = 6) and chloride channel blockers (n = 6). Pretreatment with BUM, HEPES without bicarbonate, ETH, 4,4’-diisothiocyano-2,2’-stilbene-disulfonic acid, A9C or niflumic acid at half-maximal inhibitory concentration significantly decreased the contractility induced by norepinephrine at ED80. All P < 0.01 DISCUSSION Chloride-dependent mechanisms are increasingly recognized as contributors to SM excitability; however, their role in urinary bladder SM remains incompletely understood. In the present study, alteration of extracellular chloride conditions and pharmacological interference with chloride-related pathways consistently attenuated bladder SM contractility under ex vivo conditions. These findings support the functional involvement of chloride-dependent signaling in the regulation of bladder SM tone. Previous studies of chloride-dependent SM regulation have been conducted mainly in vascular, airway, gastrointestinal, and urethral tissues, where chloride conductance has been associated with membrane excitability and calcium-dependent contraction [892223242526]. In contrast, direct evidence in urinary bladder SM remains limited and has focused primarily on spontaneous or phasic activity associated with CaCC signaling [1516]. Therefore, extrapolation from nonbladder SM systems to detrusor physiology should be made cautiously. In the present experiments, reduction of extracellular chloride concentration and substitution of Cl− with alternative halide ions significantly attenuated contractile responses. However, low extracellular chloride may also alter intracellular chloride homeostasis, membrane electrochemical gradients, and transporter activity [27]; therefore, the observed inhibitory effects cannot be attributed solely to direct chloride-channel inhibition. The broad range of extracellular chloride concentrations used in this study was intended primarily for mechanistic investigation of chloride-dependent signaling rather than simulation of physiological bladder conditions. Although such ionic manipulation is commonly used in ion-channel physiology studies, extreme chloride reduction may additionally affect membrane excitability and intracellular ionic balance. Therefore, the findings should be interpreted as evidence supporting the involvement of chloride-dependent mechanisms in bladder SM contractility. The halide substitution experiments also require cautious interpretation. Br− and I− are not biologically inert substitutes for Cl − and may interact differently with chloride channels, transporters, and passive membrane conductance pathways [28]. Differences in ion permeability and channel selectivity may therefore contribute to the differing effects observed between Br⁻ and I⁻ substitution [29]. Accordingly, these findings suggest that bladder SM contractility is influenced not only by chloride ions themselves but also more broadly by extracellular anion composition and chloride-dependent ionic regulation. The present study additionally utilized multiple pharmacological approaches to interfere with chloride-dependent pathways, including bumetanide, bicarbonate-free HEPES-buffered solution, ethacrynic acid, DIDS, A9C, and NFA. These agents were selected because they are widely used pharmacological tools for investigating chloride-dependent mechanisms in SM physiology. Bumetanide and ethacrynic acid were used to inhibit chloride transport, whereas DIDS, A9C, and NFA were used as chloride-channel/CaCC inhibitors. Bicarbonate-free HEPES buffer was additionally used to reduce bicarbonate-dependent chloride transport activity [18192021]. The use of multiple agents with different primary targets was intended to determine whether disruption of chloride-dependent pathways would produce consistent effects on bladder SM contractility. However, none of these compounds are fully selective. Bumetanide and ethacrynic acid may alter cellular ionic homeostasis beyond chloride transport inhibition, whereas DIDS, A9C, and NFA are known to affect multiple ion conductances, membrane excitability pathways, intracellular calcium handling, and anion transport systems. Therefore, the observed inhibitory effects cannot be interpreted as definitive evidence for direct involvement of specific chloride transporters or channel subtypes. Nevertheless, the consistent reduction in contractility observed across multiple mechanistically distinct interventions supports the conclusion that chloride-dependent pathways contribute functionally to bladder SM contraction. In addition to the pharmacological findings, Western blotting and immunohistochemistry demonstrated expression of ClC-3 and CLCA4 in both urothelial and SM layers of rat bladder tissue. These observations provide supportive molecular evidence that chloride-related signaling pathways are present in multiple bladder compartments potentially involved in regulation of bladder contractility. ClC-3 was selected because previous studies have implicated this chloride transporter/channel-associated protein in regulation of membrane excitability, cell volume homeostasis, and SM function [73031]. Detection of ClC-3 expression in bladder SM is therefore consistent with the possibility that chloride-dependent transport mechanisms contribute to detrusor contractility. In addition, urothelial expression of ClC-3 may be functionally relevant because the urothelium is increasingly recognized as an active signaling structure capable of modulating underlying SM activity through release of ATP, nitric oxide, and other paracrine mediators [32]. CLCA4 was evaluated as a chloride channel-associated regulatory protein potentially related to calcium-dependent chloride signaling pathways. Members of the CLCA family have historically been associated with CaCC activity and epithelial chloride conductance [33]. However, CLCA proteins are not currently considered definitive pore-forming CaCC channels and are thought instead to function primarily as regulatory or accessory proteins that indirectly modulate chloride-channel expression or activity [34]. Therefore, CLCA4 expression in the present study should be interpreted as supportive rather than definitive evidence for functional CaCC signaling in bladder tissue. The detection of both ClC-3 and CLCA4 within urothelial and SM layers raises the possibility that chloride-dependent pathways participate in urothelial–SM communication. Chloride-dependent conductance pathways within urothelial cells may influence membrane excitability, intracellular ionic balance, or release of signaling mediators capable of modulating SM tone. Likewise, chloride-related mechanisms in SM cells may contribute directly to contractile regulation. However, the present study did not directly investigate functional interactions between urothelial and SM chloride signaling pathways, and therefore these interpretations remain speculative. Interpretation of CaCC involvement also requires caution. Ano1/TMEM16A is currently regarded as the principal molecular candidate underlying CaCC activity in SM tissues [23242526], and previous bladder studies have demonstrated Ano1 expression and suggested a role in spontaneous phasic contractility [1516]. However, the precise contribution of CaCC signaling to sustained agonist-induced tonic contraction in bladder SM remains incompletely defined. The NFA findings deserve particular consideration because previous studies have reported that low concentrations of NFA may enhance spontaneous phasic or agonist-induced detrusor activity [35]. This apparent discrepancy may reflect concentration-dependent pharmacological effects, differences between spontaneous phasic activity and sustained tonic contraction, or nonspecific effects of NFA on multiple ion conductance pathways. In the present study, NFA consistently attenuated NE-induced tonic contraction, suggesting that chloride-dependent conductance pathways may contribute differently to sustained contractile states than to spontaneous phasic activity. The present experiments utilized NE-induced contraction as a model of sustained agonist-mediated SM activation. Although physiological bladder emptying is mediated predominantly through cholinergic and purinergic pathways, NE was selected because it produces relatively stable tonic contraction under organ bath conditions, thereby facilitating assessment of chloride-dependent modulation of sustained contractility. Nevertheless, different agonists may engage distinct intracellular signaling pathways, and the present findings may not fully reflect chloride-dependent mechanisms involved in physiological muscarinic or purinergic bladder contraction. Further studies are warranted. Several limitations of this study should be acknowledged. The present findings provide functional pharmacological evidence that chloride-dependent pathways contribute to bladder SM contractility; however, they do not establish that bladder SM utilizes chloride-dependent mechanisms identical to those previously described in vascular SM. In addition, intracellular calcium signaling, membrane depolarization, chloride flux, and electrophysiological activity were not directly measured. Therefore, mechanistic interpretations regarding CaCC activation and chloride-dependent membrane conductance remain inferential and based primarily on previous literature. Furthermore, some extracellular chloride conditions used in this study exceeded physiological ranges and were intended mainly for mechanistic investigation rather than simulation of normal bladder physiology. Finally, species differences and the ex vivo experimental design may limit extrapolation of these findings to human bladder physiology and pathological conditions. CONCLUSION The present study provides convergent pharmacological and molecular evidence supporting a contributory role of chloride-dependent signaling in bladder SM contractility under ex vivo conditions. Alteration of extracellular chloride conditions and pharmacological interference with chloride-related pathways consistently attenuated contractile responses, while expression of ClC-3 and CLCA4 in urothelial and SM layers suggests that chloride-dependent regulation may involve multiple bladder compartments. Although the precise molecular and electrophysiological mechanisms remain incompletely defined, these findings support further investigation into chloride-dependent ionic signaling in bladder physiology and dysfunction. Data availability statement The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request. Conflicts of interest There are no conflicts of interest. SUPPLEMENTARY MATERIAL A standard contraction curve showing the maximal contraction (max point) and tension at the 20-min time point (end point). The initial contractile response has been attributed to direct activation of the contractile proteins by Ca2+ released from the sarcoplasmic reticulum. A second, important function of this Ca2+ pool is to activate a depolarizing Cl− current. This depolarization results in the influx of extracellular Ca2+, which is responsible for the second, or maintained, phase of contraction